Females, Aging, Metabolism, and Exercise
Completed · Not applicable · Has a placebo group
Conditions studied: Obesity
In brief
This study is designed to determine whether a reduction in hormones (such as occurs during menopause) causes a decrease in calories burned during physical activity. This study will also determine whether a reduction in hormones decreases calories burned while sleeping, resting, and eating and whether an exercise intervention can prevent this.
Key facts
- Study ID
- NCT01712230
- Run by
- University of Colorado, Denver
- People needed
- 47
- Starts
- 2012-10-01
- Expected to finish
- 2017-10-01
- Last updated by the study team
- 2019-11-22
Who can join
Age: 40 and older, up to 60. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Healthy women aged 40 to 60 years
- Are still experiencing regular menstrual cycles.
- They must be willing to be randomized to placebo or GnRHAG therapy for 24 weeks
- Be physically able to be randomized to participate in a programmed exercise training program.
- The investigators will consent up to 132 subjects with the aim of enrolling 22 in each of the 3 groups (placebo, GnRHAG, or GnRHAG+Exercise).
You may not qualify if…
- irregular menstrual cycles defined as 2 or more missed cycles in the previous year
- serum FSH >25 mIU/mL measured during the first 5 days of the menstrual cycle
- on hormonal contraceptive or menopausal therapy
- positive pregnancy test
- intention to become pregnant or start hormonal contraceptive therapy during the period of study
- lactation
- known hypersensitivity to GnRH or leuprolide acetate
- score >16 on the CESD((Center for Epidemiologic Studies Depression Scale )
- severe osteopenia or osteoporosis (i.e., proximal femur or lumbar spine t scores < -2.0)
- abnormal vaginal bleeding
- thyroid dysfunction, defined as an ultrasensitive TSH <0.5 or >5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement
- uncontrolled hypertension defined as resting systolic BP >150 mmHg or diastolic BP>90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the PCP with initiation or adjustment of anti-hypertensive medications
- cardiovascular disease; subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT) without follow-up evaluation; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist
- orthopedic or other problems that would interfere with participation in the exercise program
- exercising at least 30 minutes per day at a moderate to vigorous intensity most days of the week (defined as >4 d/wk) over the past 6 months
- BMI <40 kg/m2
Where it is running
- University of Colorado - Anschutz Medical Campus — Aurora, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.